Selecta Biosciences Inc (SELB) is a clinical-stage biotechnology company that focuses on developing targeted therapies to improve the lives of patients with rare and serious diseases. The company's proprietary ImmTOR platform technology generates a novel class of products that enable the immune system to better recognize and fight disease.
Selecta's lead product candidate, SEL-212, is a combination of pegsiticase, a uricase enzyme used to treat chronic refractory gout, and ImmTOR. The company is also developing several other ImmTOR-enabled product candidates for rare diseases, including SEL-313, SEL-403, and SEL-982.
In addition to its proprietary pipeline, Selecta has established partnerships with leading pharmaceutical companies, including Sanofi, Sobi, and Asklepios BioPharmaceutical, to advance the development of gene therapies and other treatments for rare diseases.
Selecta was founded in 2008 and is headquartered in Watertown, Massachusetts.
Selecta Biosciences Inc (SELB) is a clinical-stage biotechnology company that focuses on developing targeted therapies to improve the lives of patients with rare and serious diseases. The company's proprietary ImmTOR platform technology generates a novel class of products that enable the immune system to better recognize and fight disease.